Lonza Completes 6000m² Expansion for QC and Bioanalytics in Basel

• Lonza completes the expansion of its Drug Product Services (DPS) facility in Basel, Switzerland.

• The new 6000m² facility boosts quality control and bioanalytics capacity to meet rising demand for biologic drug products.

Lonza has completed the expansion of its Drug Product Services (DPS) site in Basel, Switzerland, adding a new facility for quality control (QC) and bioanalytics. The 6000m² addition will support both clinical and commercial projects, allowing the company to increase capacity in response to the growing demand for biologic drug products.

The new space, which includes state-of-the-art laboratories and offices, enables Lonza to double its capacity for developing and testing parenteral dosage forms. This expansion is part of the company’s broader strategy to enhance its biologics manufacturing capabilities, supporting its customers’ progress from early-stage development through to commercialization.

Peter Droc, Head of Drug Product Services at Lonza, said, “Expanding Lonza’s drug product capacity is a key enabler of our wider Biologics strategy to offer drug developers a seamless solution across modalities, from early development to drug substance and drug product manufacture.”